Two-drug combination shows promise against treatment-resistant prostate cancer in preclinical study

The short version

• University of Michigan researchers discovered that combining two drug types reversed cellular alterations and slowed tumor growth in preclinical prostate cancer models.[ScienceDaily]
• The approach targets transdifferentiation, a survival mechanism where cancer cells change identity following the loss of TP53 and RB1 genes.[ScienceDaily]
• One component, DNMT inhibitors, is already FDA-approved for other conditions such as blood cancer.[ScienceDaily]
• The findings remain in preclinical stages, and clinical trials have not yet been conducted in human patients.[ScienceDaily]

Key facts

• University of Michigan researchers found that pairing two drug types slowed tumor growth and reversed cellular changes in preclinical testing.[ScienceDaily]
• Transdifferentiation in prostate cancer involves cells adopting alternative identities and is associated with the loss of TP53 and RB1 genes.[ScienceDaily]
• BET bromodomain inhibitors slowed cell growth in prostate cancer lines but were insufficient to kill the cells alone.[ScienceDaily]
• DNMT inhibitors have previously obtained FDA approval to treat other diseases, including blood cancer.[ScienceDaily]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• Scientists find a new weakness in treatment-resistant prostate cancerScienceDaily - Health